Therapeutic AreaFormulary ChoicesCost for 28
(unless otherwise stated)
Rationale for decision / comments
For topical antivirals please refer to Chapter 13: Skin
All intravenous and some oral formulations are red drugs and therefore to be provided by secondary care. These are explained in the Traffic Light System

For detailed guidance see Somerset Infection Management Guidance
Influenza vaccines
Influenza vaccine Tri-valent intramuscular injectionFor active immunisation against the influenza infection as part of the UK national immunisation programme
Companies offer a range of deals & discounts depending on service package. The CCG has a duty to recommend that practices make best use of the available NHS resources and purchase a vaccine that is both cost effective and has a supplier who can provide sufficient practice support to ensure good uptake by patients. Given the choice of the different vaccines Somerset CCG sees no reason for a practice to choose a vaccine with an NHS price > £5.50
The Joint Committee on Vaccination and Immunisation states that vaccines should only be administered within the licensed age range:
2016/17 seasonFirst line:

Enzira®
Influvac®
Fluarix®


£5.25 per dose
£5.22 per dose
£5.39 per dose

Licensed for adults and children from 5 years of age
Licensed for adults and children from 6 months of age
Licensed for adults and children from 6 months of age
2017/18 seasonFirst line:

Enzira®
Influvac®
Fluarix®


£5.25 per dose
£5.22 per dose
£5.39 per dose

Licensed for adults and children from 5 years of age
Licensed for adults and children from 6 months of age
Licensed for adults and children from 6 months of age
Nasal vaccineFluenz Tetra®▼£180.00 (10)For active immunisation against the influenza infection as part of the UK national immunisation programme:
 All infants aged two years and three years (but not four years or older) on 1 September 2013, or;
 Children aged 4 to 17 years who are in a clinical risk group category listed in Chapter 19 of the Immunisation Against Infectious Disease
Shingles Vaccine (Varicella zoster Vaccine)Zostavax® is recommended for active immunisation of individuals aged 70 years or 79 years for the prevention of herpes zoster (“zoster” or shingles) and herpes zoster-related post-herpetic neuralgia (PHN) as part of the UK national immunisation programme: Supply is limited & prescribing not currently recommended on NHS FP10.